Ticker: LLY

Eli Lilly

Pharma Healthcare Drug Manufacturers - General
Price 1203.14
Reco Buy Potential 83 Risk 28 Updated 2026-07-27

Forecast impact

positive
Target +15.8% target fill 86.4%
Reaction D5 +0.63% · D10 +2.64% fresh confirmed · market trust
Impact Potential +6 · Risk -3 valid until 2026-08-13

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell
Description

Company and Business Model

Eli Lilly is a global healthcare company that focuses on the discovery, development, and commercialization of pharmaceuticals. Its core products include treatments for diabetes, oncology, immunology, and neurodegenerative diseases. Major business segments consist of diabetes care, oncology, and neuroscience, with significant revenue generated from insulin products and cancer therapies. The company is recognized for its innovative drug pipeline and strong market presence in the healthcare sector.

Investment Profile

Eli Lilly's stock is positioned as a balanced investment, appealing to investors seeking moderate growth and some income through dividends. The company demonstrates stable revenue growth and a consistent dividend yield, making it suitable for those looking for a mix of capital appreciation and income. Its established market presence and ongoing product development contribute to a favorable risk-return profile.

Fundamental metrics (experimental) Updated: 2026-07-24
EPS (TTM) — earnings per share for the last 12 months, $
28.20
Revenue QoQ — quarter-over-quarter revenue growth
2.6%
EPS surprise
22.7%
20d volatility
1.6%
Dividend yield
0.7%
last ex-date
2026-08-14
AI recommendation changes
Date Before After Reason
2026-05-18 Hold Buy Strong fundamentals and positive short-term momentum.
2026-05-10 Buy Hold Weak momentum and high risk; mixed analyst signals.
2026-05-08 Buy Solid fundamentals but mixed momentum signals.
Analyst forecasts
Date Analyst Action Target Price Then
2026-07-14 Bernstein Target Raised — → 1385 1185.08
2026-07-13 UBS Target Raised 1250 → 1425 1189.91003
2026-07-13 Guggenheim Target Raised — → 1273 1188.58
News Page 3 of 4
Novo Nordisk Eli Lilly

Novo Nordisk and Eli Lilly Compete for Dominance in the GLP-1 Pill Market Ahead of Medicare Coverage

Novo Nordisk and Eli Lilly are intensifying their competition in the GLP-1 pill market as they prepare for Medicare coverage, which could significantly increase access to their obesity treatments. Both companies are focusing on marketing strategies to appeal to seniors, who will soon be able to access these medications at a reduced cost.
SpaceX Wells Fargo Intel Broadcom Eli Lilly

Stock Market Experiences Significant Decline Following Strong Jobs Report and Disappointing Earnings from Tech Companies

Last week's stock market experienced a significant downturn, primarily driven by disappointing earnings from major tech companies and a strong jobs report that diminished expectations for a Federal Reserve interest rate cut. This shift has raised concerns about the sustainability of recent market highs and the potential impact of increased stock supply from upcoming IPOs.
Eli Lilly

Eli Lilly’s Business Development Head Jacob Van Naarden Signals Increased M&A Activity as Company Pursues New Opportunities

Eli Lilly is leveraging its significant financial strength, driven by its successful weight loss drugs, to pursue an aggressive acquisition strategy aimed at diversifying its drug pipeline and expanding into new therapeutic areas. This shift marks a notable change in Lilly's approach to dealmaking as it seeks to capitalize on its recent growth.
Micron Advanced Micro Devices Exxon Mobil Intuitive Machines AutoZone Ferrari Chevron Qualcomm Eli Lilly

Stocks to Watch: AutoZone Declines on Sales Challenges, Eli Lilly Acquires Three Companies, Ferrari Launches Electric Vehicle, and Lear Upgraded by TD Cowen

Several companies are experiencing notable stock movements ahead of the market opening, with AutoZone facing declines due to disappointing international sales, while Eli Lilly's acquisition strategy boosts its stock.